Participants 89 145 7
patients with locally advanced resectable rectal cancer.
Participants 363 721 7
Patients with stage II/III LARC received capecitabine 1250 mg/m(2) twice daily for 2 weeks followed by intravenous cetuximab 400 mg/m(2) at week 3, then weekly intravenous 250 mg/m(2) cetuximab plus CRT including capecitabine 825 mg/m(2) twice daily (including weekends during radiotherapy) with radiotherapy of 45 Gy (25 x 1.8 Gy), 5 days a week for 5 weeks
Participants 873 933 6
Thirty-seven patients were eligible for safety and efficacy.
Participants 1687 1716 4
patients with resectable LARC
